Figure 4

Co-treatment of N-BPs and TRAIL affects prenylation in MG 63 cells. (A, B, E) MG 63 cells were pretreated with 50 µM alendronate (A) or 100 µM risedronate (B) 10 µM GGOH and/or cholesterol and/or 100 µM Z-VAD-fmk (E) for 24 h with/without 400 ng/ml of TRAIL for an additional 4 h. Following treatment, MG 63 cell lysates were collected and immunoblotted with antibodies specific for unprenylated Rap 1A and β-actin. (C) MG 63 cells were pretreated with 50 µM alendronate, 10 µM GGOH and/or cholesterol for 24 h with/without 400 ng/ml TRAIL for an additional 24 h. Cell viability was determined by crystal violet staining. Viablility of control cells was set at 100%, and viability relative to the control is presented. (D) MG 63 cells were treated as described in Figure 2D and total cholesterol levels were measured and normalized to protein concentration. ^*Indicates a significant difference from control (^*P<0.05, ^**P<0.01). ^#P<0.05. The experiments were repeatedly performed to confirm the results.